Literature DB >> 19465405

How Much of CAM Is Based on Research Evidence?

Edzard Ernst1.   

Abstract

The aim of this article is to provide a preliminary estimate of how much CAM is evidence-based. For this purpose, I calculated the percentage of 685 treatment/condition pairings evaluated in the "Desktop Guide to Complementary and Alternative Medicine" which are supported by sound data. The resulting figure was 7.4%. For a range of reasons, it might be a gross over-estimate. Further investigations into this subject are required to arrive at more representative figures.

Entities:  

Year:  2011        PMID: 19465405      PMCID: PMC3136881          DOI: 10.1093/ecam/nep044

Source DB:  PubMed          Journal:  Evid Based Complement Alternat Med        ISSN: 1741-427X            Impact factor:   2.629


1. Introduction

A lively discussion exists about the question as to how much of conventional medicine might be based on sound evidence [1]. One figure that is often cited is 15% [2]. It presents, however, unreliable and out-dated information: the figure can be traced back to a small survey conducted in 1960/61 of prescribing practises of family doctors in a northern British town, which looked toward controlling prescribing costs [3]. Other experts have published more convincing data showing that an average of 76% of interventions are supported by some form of compelling evidence, with an average of 37% of interventions being supported by randomized clinical trials (RCTs) [3]. A recent systematic review [4] of the topic found that, in general internal medicine, over 50% [5] and in psychiatry over 65% [6] of interventions are based on positive data from RCTs. The discussion about the evidence-base of CAM is far less lively. Here I present a first attempt to generate some data and hopefully a constructive discussion on this potentially important subject.

2. Methods

As a basis for my assessment, I used our own book The Desktop Guide to Complementary and Alternative Medicine [6]. In this book, we evaluate the research evidence from clinical trials and systematic reviews as it pertains to any type of CAM for a wide range of conditions (n = 46). For each condition, we compiled a “summary of clinical evidence” table in which the treatments are categorized according to the “weight” and “direction” of the evidence. The “weight” is conceptualized as a composite measure of the quantity, quality and level of the research evidence, which refers to the confidence that can be placed on that evidence [6]. The quantity refers to the total patient sample included in all clinical trials—there could, for instance, be five studies with an average of 20 patients resulting in a total sample of 100; this would be less than a single study with a sample of 300. The quality of the trial evidence refers to the likelihood of bias, usually estimated with a score such as the Jadad score [7]. The level of the evidence refers to the hierarchy of research evidence where systematic reviews are on top and opinion or anecdotal evidence at the bottom. The “direction” of the evidence signals whether the effect is clearly positive, tentatively positive, uncertain, tentatively negative or clearly negative [6]. The book has a full methods section to maximize transparency and reproducibility. It describes our assessments in more detail [6]. For the purpose of this analysis, I have simply counted the number of treatments which obtained the maximum “weight” and also were rated as “clearly positive” in our “summary of clinical evidence” tables. This provided the number of treatments that are supported by good evidence (if one therapy was effective for two indications it was counted twice). Subsequently, this figure was put in relation to the total number of treatment/condition pairings from all the “summary of clinical evidence” tables in our book [6].

3. Results

Fifty-one treatments were characterized as having maximum “weight” of evidence as well as being “clearly positive.” The total number of treatment/condition pairings was 685. Consequently, 7.4% of them were based on sound evidence. Table 1 provides a list of these 51 treatment/condition pairings.
Table 1

CAM treatments based on sound evidence.

InterventionConditions
AcupunctureNausea/vomiting induced by chemotherapy
AcupunctureOsteoarthritis
African plumBenign prostatic hyperplasia
Allium vegetablesCancer prevention
Aromatherapy/massageCancer palliation
BiofeedbackHypertension
BiofeedbackMigraine
ChondroitinOsteoarthritis
Co-enzyme Q10Hypertension
DietRheumatoid arthritis
Ephedra sinicaOverweight
ExerciseCancer prevention
ExerciseCancer palliation
ExerciseChronic fatigue syndrome
ExerciseDepression
ExerciseHIV/AIDS
FiberIrritable bowel syndrome
Ginkgo bilobaAlzheimer's disease
Ginkgo bilobaPeripheral vascular disease
GlucosamineOsteoarthritis
Green teaCancer prevention
Group behaviour therapySmoking cessation
Guar gumDiabetes
Guar gumHypercholesterolemia
HawthornChronic heart failure
Horse chestnutChronic venous insufficiency
HypnotherapyLabor pain
KavaAnxiety
MassageAnxiety
MelatoninInsomnia
Music therapyAnxiety
OatHypercholesterolemia
Padma 28Peripheral vascular disease
Peppermint/carawayNon-ulcer dyspepsia
PhytodolorOsteoarthritis
PhytodolorRheumatoid arthritis
PsylliumConstipation
PsylliumDiabetes
Red cloverMenopause
RelaxationAnxiety
RelaxationInsomnia
RelaxationNausea/vomiting induced by chemotherapy
S-adenosylmethionineOsteoarthritis
Saw palmettoBenign prostatic hyperplasia
SoyHypercholesterolemia
St John's wortDepression
Stress managementHIV/AIDS
Tomato (lycopene)Cancer prevention
Vitamin CUpper respiratory tract infection (treatment)
Water immersionLabor pain
YohimbineErectile dysfunction

4. Discussion

The estimate that 7.4% of CAM is based on sound evidence may well be over-optimistic. We selected the conditions for inclusion in our book [6] on the basis of two main criteria: first, the condition had to be relevant, that is, commonly seen in primary care or frequently treated with CAM and/or there had to be sufficient trial data to write a chapter. Thus, this evidence summarized in the present article represents a positive selection. Had we chosen different conditions for our book, the percentage would most likely have been lower. A glance at Table 1 furthermore informs us that several of the included modalities, for example, exercise, group behaviour therapy, stress management, fiber intake or biofeedback, could easily be classified as conventional interventions rather than CAM. Had we excluded them, the percentage of evidence-based CAM would have declined further. Finally, several cases of “sound” evidence included in Table 1 might need revision in the light of evidence that has emerged since the publication of our book. Examples include saw palmetto (Serenoa repens) [8], glucosamine [9-12], Ginkgo biloba [13-16] and acupuncture which, according to recent findings, may not be more efficacious than sham acupuncture [17, 18]. Another concern is that the present analysis merely relates to the question of how many therapies might be supported by sound research evidence. It does not address the question of how solidly CAM practice is evidence-based. This would require an assessment of which treatments are used and how often. Such a research project would be complex but would certainly be a valuable contribution to the literature. Although my estimate of how much of CAM is evidence-based draws on a critical evaluation of the available evidence, it still presents a rather optimistic view. Further investigations into this subject are required to arrive at more representative figures.
  17 in total

1.  Where is the wisdom...?

Authors:  R Smith
Journal:  BMJ       Date:  1991-10-05

2.  Assessing the quality of reports of randomized clinical trials: is blinding necessary?

Authors:  A R Jadad; R A Moore; D Carroll; C Jenkinson; D J Reynolds; D J Gavaghan; H J McQuay
Journal:  Control Clin Trials       Date:  1996-02

3.  Evidence based general practice: a retrospective study of interventions in one training practice.

Authors:  P Gill; A C Dowell; R D Neal; N Smith; P Heywood; A E Wilson
Journal:  BMJ       Date:  1996-03-30

4.  Effect of glucosamine sulfate on hip osteoarthritis: a randomized trial.

Authors:  Rianne M Rozendaal; Bart W Koes; Gerjo J V M van Osch; Elian J Uitterlinden; Eric H Garling; Sten P Willemsen; Abida Z Ginai; Jan A N Verhaar; Harrie Weinans; Sita M A Bierma-Zeinstra
Journal:  Ann Intern Med       Date:  2008-02-19       Impact factor: 25.391

Review 5.  Ginkgo biloba is not a smart drug: an updated systematic review of randomised clinical trials testing the nootropic effects of G. biloba extracts in healthy people.

Authors:  P H Canter; E Ernst
Journal:  Hum Psychopharmacol       Date:  2007-07       Impact factor: 1.672

6.  Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis.

Authors:  Daniel O Clegg; Domenic J Reda; Crystal L Harris; Marguerite A Klein; James R O'Dell; Michele M Hooper; John D Bradley; Clifton O Bingham; Michael H Weisman; Christopher G Jackson; Nancy E Lane; John J Cush; Larry W Moreland; H Ralph Schumacher; Chester V Oddis; Frederick Wolfe; Jerry A Molitor; David E Yocum; Thomas J Schnitzer; Daniel E Furst; Allen D Sawitzke; Helen Shi; Kenneth D Brandt; Roland W Moskowitz; H James Williams
Journal:  N Engl J Med       Date:  2006-02-23       Impact factor: 91.245

7.  Glucosamine/chondroitin combined with exercise for the treatment of knee osteoarthritis: a preliminary study.

Authors:  S P Messier; S Mihalko; R F Loeser; C Legault; J Jolla; J Pfruender; B Prosser; A Adrian; J D Williamson
Journal:  Osteoarthritis Cartilage       Date:  2007-06-11       Impact factor: 6.576

8.  Ginkgo biloba for prevention of dementia: a randomized controlled trial.

Authors:  Steven T DeKosky; Jeff D Williamson; Annette L Fitzpatrick; Richard A Kronmal; Diane G Ives; Judith A Saxton; Oscar L Lopez; Gregory Burke; Michelle C Carlson; Linda P Fried; Lewis H Kuller; John A Robbins; Russell P Tracy; Nancy F Woolard; Leslie Dunn; Beth E Snitz; Richard L Nahin; Curt D Furberg
Journal:  JAMA       Date:  2008-11-19       Impact factor: 56.272

9.  Saw palmetto for benign prostatic hyperplasia.

Authors:  Stephen Bent; Christopher Kane; Katsuto Shinohara; John Neuhaus; Esther S Hudes; Harley Goldberg; Andrew L Avins
Journal:  N Engl J Med       Date:  2006-02-09       Impact factor: 91.245

10.  A randomized placebo-controlled trial of Ginkgo biloba for the prevention of cognitive decline.

Authors:  H H Dodge; T Zitzelberger; B S Oken; D Howieson; J Kaye
Journal:  Neurology       Date:  2008-02-27       Impact factor: 9.910

View more
  8 in total

1.  Pharmacists' attitudes towards an evidence-based approach for over-the-counter medication.

Authors:  Lezley-Anne Hanna; Carmel M Hughes
Journal:  Int J Clin Pharm       Date:  2011-11-23

2.  When Giants Meet-a Discourse on Contemporary and Alternative Therapy Use from an Ethical Perspective.

Authors:  Cindy Shiqi Zhu; Wee Lee Chan
Journal:  Asian Bioeth Rev       Date:  2018-05-29

3.  'First, do no harm': factors that influence pharmacists making decisions about over-the-counter medication: a qualitative study in Northern Ireland.

Authors:  Lezley-Anne Hanna; Carmel M Hughes
Journal:  Drug Saf       Date:  2010-03-01       Impact factor: 5.606

4.  Observed Changes in Risk during Naturopathic Treatment of Hypertension.

Authors:  Ryan Bradley; Eva Kozura; Jennifer Kaltunas; Erica B Oberg; Jeffery Probstfield; Annette L Fitzpatrick
Journal:  Evid Based Complement Alternat Med       Date:  2011-03-13       Impact factor: 2.629

5.  Potential factors that influence usage of complementary and alternative medicine worldwide: a systematic review.

Authors:  Mayuree Tangkiatkumjai; Helen Boardman; Dawn-Marie Walker
Journal:  BMC Complement Med Ther       Date:  2020-11-23

Review 6.  Integrative veterinary medical education and consensus guidelines for an integrative veterinary medicine curriculum within veterinary colleges.

Authors:  M A Memon; J Shmalberg; H S Adair; S Allweiler; J N Bryan; S Cantwell; E Carr; C Chrisman; C M Egger; S Greene; K K Haussler; B Hershey; G R Holyoak; M Johnson; S Le Jeune; A Looney; R S McConnico; C Medina; A J Morton; A Munsterman; G J Nie; N Park; M Parsons-Doherty; J A Perdrizet; J L Peyton; D Raditic; H P Ramirez; J Saik; S Robertson; M Sleeper; J Van Dyke; J Wakshlag
Journal:  Open Vet J       Date:  2016-03-28

7.  A Retrospective Analysis of 5,195 Patient Treatment Sessions in an Integrative Veterinary Medicine Service: Patient Characteristics, Presenting Complaints, and Therapeutic Interventions.

Authors:  Justin Shmalberg; Mushtaq A Memon
Journal:  Vet Med Int       Date:  2015-12-21

8.  Randomized phase 2 study of gemcitabine and cisplatin with or without vitamin supplementation in patients with advanced esophagogastric cancer.

Authors:  A A van Zweeden; C J van Groeningen; R J Honeywell; E Giovannetti; R Ruijter; C H Smorenburg; G Giaccone; H M W Verheul; G J Peters; Hans J van der Vliet
Journal:  Cancer Chemother Pharmacol       Date:  2018-04-25       Impact factor: 3.333

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.